Gastroesophageal Reflux Disease (GERD) Global Market Report 2024

Description

“Gastroesophageal Reflux Disease (GERD) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroesophageal reflux disease (gerd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastroesophageal reflux disease (gerd)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The gastroesophageal reflux disease (gerd) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Type: Antacids; Proton Pump Inhibitors; H2 Receptor Blocker; Pro Kinetic Agents; Dopamine Receptor Antagonist; EndoCinch; Stretta; EsophyX; Transoral Incisionless Fundoplication (TIF)
2) By Procedure: Invasive; Minimally Invasive
3) By End-Users: Hospital; Homecare; Specialty Clinics
Companies Mentioned: GlaxoSmithKline PLC; SRS Life Sciences; Johnson & Johnson Services Inc.; Takeda Pharmaceutical Company Limited; AstraZeneca Plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Gastroesophageal reflux disease (GERD) is a condition characterized by the regurgitation of stomach acid into the esophagus, leading to irritation and discomfort. Treating GERD involves employing a range of medical strategies and interventions to effectively manage its symptoms and associated complications.

The primary drug categories used in the treatment of gastroesophageal reflux disease include antacids, proton pump inhibitors, H2 receptor blockers, prokinetic agents, dopamine receptor antagonists, and minimally invasive procedures such as EndoCinch, Stretta, Asphyx, and Transoral Incisionless Fundoplication (TIF). Antacids, for instance, function by neutralizing stomach acid, thus increasing the stomach's pH level to alleviate symptoms. Additionally, these treatment approaches can be divided into invasive and minimally invasive procedures, offering options that cater to the unique needs of patients. These therapies are made available through various healthcare providers, including hospitals, homecare services, and specialty clinics.

The gastroesophageal reflux disease (GERD) market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal reflux disease (GERD) market statistics, including gastroesophageal reflux disease (GERD) industry global market size, regional shares, competitors with a gastroesophageal reflux disease (GERD) market share, detailed gastroesophageal reflux disease (GERD) market segments, market trends and opportunities and any further data you may need to thrive in the gastroesophageal reflux disease (GERD) industry. This gastroesophageal reflux disease (GERD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroesophageal reflux disease (gerd) market size has grown marginally in recent years. It will grow from $5.15 billion in 2023 to $5.25 billion in 2024 at a compound annual growth rate (CAGR) of 2.0%. The growth in the historic period can be attributed to lifestyle and dietary changes, obesity epidemic, growing awareness about gerd treatment, globalization of pharmaceutical industry, investments for gerd treatments.

The gastroesophageal reflux disease (gerd) market size is expected to see steady growth in the next few years. It will grow to $5.74 billion in 2028 at a compound annual growth rate (CAGR) of 2.3%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, emergence of biomarker, growing number of screening programs for gerd, increasing prevalence of heartburn, increased demand for medical equipment. Major trends in the forecast period include diagnostic advancements, surgical advancements, development of targeted therapies, adoption of telehealth services .

High treatment costs serve as a deterrent to the growth of the proliferative diabetic retinopathy (PDR) market during the projected period. The expenses associated with diagnosing and treating PDR can pose a significant financial burden, often reaching prohibitive levels. This encompasses the costs related to frequent eye examinations, laser therapy, and, in certain cases, surgical interventions. These elevated treatment expenses create financial challenges for both patients and healthcare systems. For instance, in 2023, as reported by Medical News Today, individuals typically face annual management costs ranging from $600 to $1,000 for the treatment of diabetic eye disease, while the cost of a vitrectomy procedure falls within the range of $8,000 to $14,000. As a result, the high treatment costs emerge as a constraining factor, impeding the growth of the proliferative diabetic retinopathy (PDR) market.

A high incidence of alcohol consumption is expected to propel the growth of the gastroesophageal reflux disease (GERD) market going forward. Alcohol consumption refers to the act of drinking a beverage containing ethanol, which is the only type of alcohol that is safe for human consumption. Alcohol use contributes to the development of GERD by decreasing esophageal motility and lowering pressure levels. For instance, according to the National Institute on Alcohol Abuse and Alcoholism, a US-based government agency, in 2021, the per capita consumption of ethanol from all alcoholic beverages in the United States reached 2.51 gallons, marking a 2.9% rise from 2.44 gallons in 2020. Hence, the elevated prevalence of alcohol consumption is propelling the expansion of the gastroesophageal reflux disease (GERD) market.

The decline in drug development for gastroesophageal reflux disease (GERD) poses a significant challenge and may potentially restrict the market's growth in the foreseeable future. This decline is primarily attributed to the transformation of numerous proton pump inhibitors (PPIs) into generic and over-the-counter formulations. As a result, the availability of innovative therapeutic options for GERD patients has dwindled, particularly for those who do not achieve desirable outcomes with existing treatments. For instance, a study published in November 2021 in Frontiers in Medicine, a reputable peer-reviewed journal, underscored the persistent unmet needs within GERD management. These unmet needs encompass rapid postprandial heartburn control, enhanced relief from volume reflux and acid regurgitation, effective nighttime heartburn relief, improved acid control in patients with Barrett's esophagus, and the flexibility in proton pump inhibitor (PPI) administration schedules. The diminishing focus on drug development is predominantly linked to the majority of PPIs transitioning into generic formulations. This trend, in turn, hampers the growth of the gastroesophageal reflux disease (GERD) market.

Prominent companies operating in the gastroesophageal reflux disease (GERD) market are dedicated to the introduction of innovative treatment devices for GERD, aimed at maintaining their market leadership. For example, in April 2023, Laborie Medical Technologies, a US-based medical technology firm, unveiled the alpHaONE wireless pH-capsule reflux testing diagnostic system, designed specifically for the diagnosis of gastroesophageal reflux disease (GERD). This advanced system is capable of providing up to 96 hours of comprehensive monitoring data. Notably, it boasts a compact and user-friendly design with conveniently enlarged buttons and a dependable capsule delivery system. Moreover, it features a dedicated software application equipped with a virtual instruction program and the option for users to customize symptom buttons, thereby enhancing the overall user experience. This innovative approach is significantly impacting the evolution of the GERD treatment market.

In October 2022, Sebela Pharmaceuticals Inc., a US-based pharmaceutical company specializing in the production of gastroesophageal reflux disease medications, established a strategic partnership with HK Inno.N Corporation, a South Korea-based pharmaceutical company, in an arrangement involving an undisclosed sum. This collaboration is aimed at jointly developing and launching tegoprazan, a pioneering potassium-competitive acid blocker (P-CAB), within the US and Canada. Tegoprazan, already authorized and available in South Korea and China, holds significant promise as an innovative addition to Sebela Pharmaceuticals' gastroenterology product line, catering to individuals dealing with gastroesophageal reflux disease.

Major players in the gastroesophageal reflux disease (gerd) market are GlaxoSmithKline PLC, SRS Life Sciences, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Reckitt Benckiser Group PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, Teva Pharmaceuticals, HK inno.N Corporation, Sebela Pharmaceuticals, Mylan N.V., Bausch Health Companies Inc., Johnson & Johnson MedTech, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A., HK inno.N Corporation, SRS Life Sciences Pte. Ltd.

North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastroesophageal reflux disease (GERD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastroesophageal reflux disease (GERD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroesophageal reflux disease (GERD) market consists of revenues earned by entities by providing pharmaceutical therapies, surgical procedures and diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroesophageal reflux disease (GERD) market also includes sales of gamma-aminobutyric acid type B receptor agonists and alginate antacids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12263

1. Executive Summary

2. Gastroesophageal Reflux Disease (GERD) Market Characteristics

3. Gastroesophageal Reflux Disease (GERD) Market Trends And Strategies

4. Gastroesophageal Reflux Disease (GERD) Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Gastroesophageal Reflux Disease (GERD) Market Size and Growth

5.1. Global Gastroesophageal Reflux Disease (GERD) Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Gastroesophageal Reflux Disease (GERD) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Gastroesophageal Reflux Disease (GERD) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gastroesophageal Reflux Disease (GERD) Market Segmentation

6.1. Global Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Antacids
Proton Pump Inhibitors
H2 Receptor Blocker
Pro Kinetic Agents
Dopamine Receptor Antagonist
EndoCinch
Stretta
EsophyX
Transoral Incisionless Fundoplication (TIF)
6.2. Global Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Invasive
Minimally Invasive
6.3. Global Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital
Homecare
Specialty Clinics

7. Gastroesophageal Reflux Disease (GERD) Market Regional And Country Analysis

7.1. Global Gastroesophageal Reflux Disease (GERD) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Gastroesophageal Reflux Disease (GERD) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market

8.1. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gastroesophageal Reflux Disease (GERD) Market

9.1. China Gastroesophageal Reflux Disease (GERD) Market Overview
9.2. China Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gastroesophageal Reflux Disease (GERD) Market

10.1. India Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gastroesophageal Reflux Disease (GERD) Market

11.1. Japan Gastroesophageal Reflux Disease (GERD) Market Overview
11.2. Japan Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gastroesophageal Reflux Disease (GERD) Market

12.1. Australia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gastroesophageal Reflux Disease (GERD) Market

13.1. Indonesia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gastroesophageal Reflux Disease (GERD) Market

14.1. South Korea Gastroesophageal Reflux Disease (GERD) Market Overview
14.2. South Korea Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gastroesophageal Reflux Disease (GERD) Market

15.1. Western Europe Gastroesophageal Reflux Disease (GERD) Market Overview
15.2. Western Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gastroesophageal Reflux Disease (GERD) Market

16.1. UK Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gastroesophageal Reflux Disease (GERD) Market

17.1. Germany Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gastroesophageal Reflux Disease (GERD) Market

18.1. France Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gastroesophageal Reflux Disease (GERD) Market

19.1. Italy Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gastroesophageal Reflux Disease (GERD) Market

20.1. Spain Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market

21.1. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market Overview
21.2. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gastroesophageal Reflux Disease (GERD) Market

22.1. Russia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gastroesophageal Reflux Disease (GERD) Market

23.1. North America Gastroesophageal Reflux Disease (GERD) Market Overview
23.2. North America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gastroesophageal Reflux Disease (GERD) Market

24.1. USA Gastroesophageal Reflux Disease (GERD) Market Overview
24.2. USA Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gastroesophageal Reflux Disease (GERD) Market

25.1. Canada Gastroesophageal Reflux Disease (GERD) Market Overview
25.2. Canada Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gastroesophageal Reflux Disease (GERD) Market

26.1. South America Gastroesophageal Reflux Disease (GERD) Market Overview
26.2. South America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gastroesophageal Reflux Disease (GERD) Market

27.1. Brazil Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gastroesophageal Reflux Disease (GERD) Market

28.1. Middle East Gastroesophageal Reflux Disease (GERD) Market Overview
28.2. Middle East Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gastroesophageal Reflux Disease (GERD) Market

29.1. Africa Gastroesophageal Reflux Disease (GERD) Market Overview
29.2. Africa Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gastroesophageal Reflux Disease (GERD) Market Competitive Landscape And Company Profiles

30.1. Gastroesophageal Reflux Disease (GERD) Market Competitive Landscape
30.2. Gastroesophageal Reflux Disease (GERD) Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck and Co. Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Novartis AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Abbott Laboratories
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. GlaxoSmithKline Plc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Gastroesophageal Reflux Disease (GERD) Market Other Major And Innovative Companies

31.1. Medtronic Plc
31.2. Takeda Pharmaceutical Company Limited
31.3. Eli Lilly and Company
31.4. Amgen Inc.
31.5. Boehringer Ingelheim International GmbH
31.6. Reckitt Benckiser Group Plc
31.7. Teva Pharmaceutical Industries Ltd.
31.8. Mylan N.V.
31.9. Bausch Health Companies Inc.
31.10. Johnson & Johnson MedTech
31.11. Eisai Co. Ltd.
31.12. Sun Pharmaceutical Industries Ltd.
31.13. Perrigo Company PLC
31.14. Dr. Reddy's Laboratories Ltd.
31.15. Aurobindo Pharma Limited

32. Global Gastroesophageal Reflux Disease (GERD) Market Competitive Benchmarking

33. Global Gastroesophageal Reflux Disease (GERD) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gastroesophageal Reflux Disease (GERD) Market

35. Gastroesophageal Reflux Disease (GERD) Market Future Outlook and Potential Analysis

35.1 Gastroesophageal Reflux Disease (GERD) Market In 2028 - Countries Offering Most New Opportunities
35.2 Gastroesophageal Reflux Disease (GERD) Market In 2028 - Segments Offering Most New Opportunities
35.3 Gastroesophageal Reflux Disease (GERD) Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer